Vitiligo Drug Pipeline

Learn About the Latest Developments in Treatment

Players working on treatment therapies in various development stages.

Find out about the latest development news from pre-trial to pre-clinical stages, as well as mergers and partnerships taking place in the vitiligo space that help to attract growth and attention to this condition.

Phase One

Researchers during phase one will test and administer the drug to healthy, unaffected volunteers to evaluate the safety before proceeding with actual patients.

Villaris Therapeutics

To target the depletion of resident memory T-cells, Villaris is developing a unique humanized anti-IL-15R antibody.

Early human trials are expected to begin around 2021.

VALLAURIX / Clinuvel Pharmaceuticals

The peptide sequence in Parvysmelanotide (VLRX001) makes it less sensitive to degradation than physiologic (natural) alpha-melanocyte-stimulating hormone (a-MSH).

Bioniz Therapeutics / Almirall

BNZ-1 for vitiligo, cutaneous T-cell lymphoma, and alopecia areata immuno-dermatology franchise.

The primary product candidate has successfully completed Phase 1 SAD and MAD clinical studies in healthy volunteers and is currently in Phase 1/2a CTCL clinical development.

AXIM Biotechnologies

AX-1602 is the drug candidate.

A patent application for a method of treating vitiligo with a topical formulation including cannabidiol and cannabigerol has been filed by AXIM.

No other specific details are currently available.

Boston Pharmaceuticalss

BOS-475 (previously GSK3183475), a topical chemical, was in-licensed by the company to treat vitiligo and psoriasis.

This Phase I-ready drug is a small molecule Bromodomain and Extra-Terminal inhibitor. It inhibits the expression of pro-inflammatory mediators, including IL-17 and chemokines associated with Th1.

Arrien Pharmaceuticals

Arrien is working on ARN-4079, an orally accessible JAK3 inhibitor that targets the unique Cys909 residue at the gatekeeper location.
They intend to submit an IND for the treatment of vitiligo and other skin ailments.

Arrien is looking for collaborations to assist it complete IND-enabling investigations and Phase I clinical trials.

Aché Laboratórios Farmacêuticos

ANVISA, the Brazilian regulatory body, recommended that the Phase 3 research for drug candidate ACH24 be canceled in order to undertake a Phase 1 study first in 2016.

No other specific details are currently available.

Temprian Therapeutics

The company is currently seeking partnerships to further the development of TT-01, a DNA-based vitiligo therapy.

Professor Caroline Le Poole of Northwestern and Loyola Universities designed a modified HSP70i for it.

Rheos Medicines

For lupus and vitiligo, they are concentrating on inhibiting T-cell effector responses.

Their goal is to alter metabolic pathways in immune cells, specifically CD4 and CD8 T cells.

LSI (Life Science Investments)

VITILSI is in pre-clinical testing at the moment.

This is the only plant-based cosmeceutical formulation in development that combines antioxidant, anti-inflammatory, and immunomodulatory capabilities with melanogenesis-inducing properties of Coleus forskohlii root and Cassia alata leaves extract.

Palatin Technologies

In 2013, Palatin filed a patent application for melanocortin receptor-1 peptides (MC-1).

No other specific details are currently available.

Castle Creek Pharma

CCP-070 is a pre-clinical drug candidate for a “rare dermatologic disease.”

Professor Abdel-Malek of the University of Cincinnati in-licensed these tri- and tetra-peptide melanotropic analog series to the corporation.

After topical administration, promising peptide structures are tiny enough to penetrate the dermis.

Phase Two

Researchers during phase two will administer the drug to vitiligo patients to create studies on how beneficial it can be.


The efficacy and safety profile of PF-06651600, a selective JAK1 inhibitor, and PF-06700841, a tyrosine kinase 2(TYK2)/JAK1 inhibitor, are being evaluated in people with active non-segmental vitiligo in a Phase 2b/3 program.

Arcutis Biotherapeutics

The active ingredient of ARQ-252, SHR0302, is a strong and highly selective janus kinase type 1 inhibitor (JAK1).
This drug, according to Arcutis, shows promising therapeutic potential without the hematological side effects associated with JAK2 inhibition.
Arcutis plans to start a Phase 2a trial in the second half of 2020.

Dermavant / Roviant Sciences

Cerdulatinib, a topical JAK/Syk inhibitor, is being used to advance a pipeline of therapy options for vitiligo and other disorders.
Also named DMVT-504 or RVT-502, in-licensed from Portola Pharmaceuticals for topical indications.

Phase Three

Researchers during phase three will demonstrate whether or not a drug benefits vitiligo candidates with detailed data on safety and more.


Ruxolitinib is a well-known JAK1/JAK2 inhibitor with an excellent safety profile.

It treats vitiligo by reducing the body’s immune system’s hyperactive TH1 arm, which is responsible for depigmentation.

Most patients achieved over 50% repigmentation following all four doses of topical ruxolitinib.

1/3 of patients had complete facial repigmentation at 24 weeks.

Subscribe to our Newsletter

Are you dealing with a recent diagnosis or know someone who has vitiligo? We’re here to help you figure out what works best to manage symptoms and improve overall day-to-day life whether you or someone you love is affected.

This field is for validation purposes and should be left unchanged.